Quality of Life Significantly Improved with Erlotinib for NSCLC - MPR
Links shared publicly online about this topic.
- 238total visits
Quality of Life Significantly Improved with Erlotinib for NSCLC - MPR
empr.com —
View full resource at empr.com
Tags: Cancer Medication, Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer Medication, Lung, Gemzar, Tarceva
Most Recently Shared on June 6, 2011 at 9:01 pm By:
#asco2011 Quality of Life Significantly Improved with Erlotinib for NSCLC http://goo.gl/fb/t31b1
Stutent Did Not Improve Overall Survival In Patients With Previously Treated Advanced Non-small Cell Lung Cancer - QualityPoint Technologies
qualitypointtech.net — “The SUN 1087 trial of Stutent (sunitinib malate) combined with erlotinib versus just elrotinib did not improve overall survival in patients with previously treated NSCLC (non-small cell lung cancer), Pfizer Inc. informs. However, the combination therapy did demonstrate a significant improvement in progression free survival.. The study's primary endpoint was overall survival, while progression-free survival was a secondary endpoint. Trial participators and clinicians reported no unexpected types ” View full resource at qualitypointtech.net
Most Recently Shared on August 25, 2010 at 2:12 am By:
Stutent Did Not Improve Overall Survival In Patients With Previously Treated Advanced Non-small Cell Lung Cancer: ... http://bit.ly/9ZiuGW
Topline Results From Phase 3 Trial Of Sunitinib With Erlotinib In Advanced Non-Small Cell Lung Cancer (NSCLC) - QualityPoint Technologies
qualitypointtech.net — “Pfizer Inc. (NYSE :PFE) announced that the SUN 1087 trial of sunitinib in combination with erlotinib versus erlotinib demonstrated a statistically significant improvement in Progression-Free but not in Overall Survival in patients with previously treated advanced non-small cell lung cancer (NSCLC). Overall survival was the primary endpoint of the study and Progression-Free Survival was a secondary endpoint of the study. No new or unexpected types of adverse events were observed in the study...” View full resource at qualitypointtech.net
Most Recently Shared on August 24, 2010 at 1:03 pm By:
Topline Results From Phase 3 Trial Of Sunitinib With Erlotinib In Advanced Non-Small Cell Lung Cancer (NSCLC): Pfi... http://bit.ly/dgKbto
Advertisement
